Fig. 7

FLVCR1a modulates the angiogenic potential of human tumor-derived ECs in vitro. A qRT-PCR analysis showing FLVCR1a mRNA levels in normal (Hmec) and tumor-associated (Btec) human ECs. B Western Blot analysis showing FLVCR1a protein expression in Btec and Hmec. The protein quantification is shown in C. Proliferation of control Btec (scr), FLVCR1a-silenced Btec (flv), and Hmec at multiple time points. E in vitro tubulogenesis assay performed with control (scr) and FLVCR1a-silenced (flv) Btec. F–H Quantification of F number of nodes, number of G master junctions, and H total length of the networks obtained with Btec-scr and Btec-flv. I Transendothelial resistance (TEER) measurement performed on control (scr) and FLVCR1a-silenced (flv) Btec. Data are representative of at least 3 independent experiments and are expressed as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. For statistical analyses, an unpaired Student’s t test was used